1. 225OImpact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. (24th November 2019) Authors: Friedlander, M L; Hettle, R; Parkhomenko, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 231PCost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore. (24th November 2019) Authors: Tan, D S; Chan, J J; Loke, J K; Hettle, R; Ghosh, W; Viswambaram, A; Yu, C C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). (24th November 2019) Authors: Friedlander, M L; Moore, K N; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E; Hettle, R; Flood, E; Disilvestro, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗